2025 H1 -tulosraportti
155 päivää sitten48 min
Tarjoustasot
First North Denmark
Määrä
Osto
3 910 551
Myynti
Määrä
6 211 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 115 | - | - | ||
| 450 000 | - | - | ||
| 2 500 | - | - | ||
| 70 000 | - | - | ||
| 227 272 | - | - |
Ylin
0,002VWAP
Alin
0,002VaihtoMäärä
0 3 370 143
VWAP
Ylin
0,002Alin
0,002VaihtoMäärä
0 3 370 143
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9.2025 | |
| 2024 H2 -tulosraportti | 29.4.2025 | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·7 t sittenOverview ….. 🇦🇺 Australia: The Bridgehead to Asia-Pacific Australia is a central part of the company's global scaling strategy. Here are the specific points: • Validation of Ayla: Brain+ is working with leading Australian experts to ensure that their digital CST platform (Ayla) is culturally and clinically adapted to the Australian market. • Partnerships: The focus is on building relationships with Australian healthcare organizations that are seeking digital tools to manage the increasing dementia burden. • Scalability: Australia is seen as a test market for how the product can be rolled out in English-speaking regions outside Europe, which increases the company's value in connection with a potential sale or partnership. 🛠️ Status of the Restructuring (February 2026) This is where Devika is currently spending most of her time to ensure the company's survival: • Creditor Negotiations: The company is in close dialogue with the trustee (Søren Volder). The goal is to clear up the debt so that Brain+ becomes an attractive investment again or can be sold. • Postponement of plan: The meeting regarding the final restructuring plan has just been proposed to be postponed to March 13, 2026. This is often interpreted as a positive sign that a real solution is being worked on rather than just a liquidation. • Focus on the core: Everything unnecessary has been cut. Devika is 100% focused on proving the value of the CST platform in the UK and Denmark to show the trustee that there is a sound business beneath the surface. 🚀 Commercial focus: UK and Denmark Even though there is noise around the economy, daily operations continue: • United Kingdom: Work with large nursing homes (like Agincare) continues. This is where the large volume contracts are to be secured. • Denmark: Brain+ maintains its position as a pioneer in the home market, which serves as a "proof-of-concept" for international markets
·3 t sittenLittle andersbjørn and bøhman. This is a debate, and by definition, in a debate there must be room for both for and against. I know very well that you and the rest of the cheering squad don't understand a thing about it. You don't want debate, you cannot tolerate counter-arguments. You are only interested in hearing what you want to hear. I remind you, you have the option to mute me, please use it. Or use the advice I have given previously, that you create a Facebook group. Then you can sit and enjoy yourselves in it, well-protected, undisturbed and completely unopposed, and where you self-satisfied can enjoy your very own pseudo back-patting debate, where you are all oh so in agreement that you alone know, that you alone have insight, that you will get stinking rich on Brain and that Devika is God…all while you lose more and more money, but that doesn't matter, because you are right regardless - even when the money is 100% gone….hehehe
·2 t sittenOverleif, maybe you could help us who are trying in the background to help Brain+ and save our assets, and possibly ask your niece, who, in relation to dementia coordinators, has decision-making power regarding the purchase of Ayla? That could help us who are actually trying to save Brain+, by contacting the right place. Ultimately, it might also give you some positive reception and take some of the pressure off. So, do you want or have the opportunity to ask your niece about the above and possibly whether it is dementia coordinators in general who cannot make the decision about buying Ayla or if some can? I am sure that you can actually become a resource, but we just need to find a way to bring that out. Do you perhaps have any suggestions on how we can help Brain+, possibly oonåelig funding to get past reconstruction and back to daily operations? I am not cutting you down, but here is an opening to help us who are trying to help Brain+ and I hope that you will accept the extended hand. Hope to hear your thoughts. Good day.- ·8 t sitten( Skeptical ) "I can certainly understand the skepticism about the historical downgrades – the numbers haven't kept up with the rhetoric until now, we agree on that. But there are a few nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) rest on external research and evidence that is internationally recognized. It's not something Devika has sat and made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream-rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum-talk', but about the administrator's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product, is a more difficult discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I don't invest in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more."
·5 t sittenSo there can be a reconstruction where current shareholders retain their shares? - ·9 t sitten(Also writing the answer here with Devika ) "I do not agree that Devika is untrustworthy, but one must distinguish between a difficult market situation and personal credibility. Here are a few reasons why I still have faith in her work: 1. Product focus and execution: Under her leadership, Brain+ has actually delivered on the technical and clinical milestones. They have launched the CST products (Cognitive Stimulation Therapy) and created partnerships both in Denmark and internationally (e.g., in the UK). These are difficult results to achieve in the medtech industry. 2. Transparency during restructuring: It was the management itself that chose to enter restructuring to protect the company when long-term financing failed. This is a responsible action towards creditors and the company's future, rather than just letting it go bankrupt without a fight. 3. Tough market for Small Cap: The entire sector for small growth companies has been hit by an extreme drought in capital injection over the last few years. That the share price falls in such a market is rarely solely the CEO's fault, but rather an expression of a lack of market liquidity. 4. Her insight: She comes with deep experience from the industry, and it is she who has the network to secure the deals that will save the company now. Changing captain in the middle of a storm (restructuring) would be far more risky. Let's see what the plan from the administrator and management brings before we judge her. The most important thing right now is to save the assets for all involved
·10 t sitten · MuokattuI understand the situation for Brain+ is critical and I also have money at stake, although it sounds like it's not as much as others here. I am absolutely thrilled with the support that many are giving here and the work being put into helping Brain+ as much as possible... my BUT is that this work and this media attention that suddenly arises from this community, shouldn't it have been done by the company and perhaps already 2 years ago and continuously? I have all respect for the time you put into, of course, saving your own money, but there should have been a company that had already thought about and acted on all these initiatives that are now being put into play? There are many ways to run a company, I won't pretend to be an expert on that, but all in all, I miss some information and more announcements. It could also easily be that I don't fully understand all of this and expect them to react like multi-billion dollar companies..·8 t sittenI can certainly understand your skepticism about the historical downgrades – the numbers haven't matched the rhetoric until now, we agree on that. But there are a couple of nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) are based on external research and evidence that is internationally recognized. It's not something Devika just made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum talk', but about the trustee's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product is a harder discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I'm not investing in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more. Thanks for the good luck wish – in this end of the market, you always need a bit of luck, but I base my plan on the substance that, after all, lies in the product once the dust from the reconstruction has settled.·8 t sittenAnd adds that the price seeming low is in no way an indication that the stock is cheap. In fact, quite the opposite. It is a fact that stocks priced at such a level actually and very concretely belong among the supremely most expensive on the stock exchange, when assessed based on key figures and especially risks.
·1 päivä sittenNice with feedback
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 H1 -tulosraportti
155 päivää sitten48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenOverview ….. 🇦🇺 Australia: The Bridgehead to Asia-Pacific Australia is a central part of the company's global scaling strategy. Here are the specific points: • Validation of Ayla: Brain+ is working with leading Australian experts to ensure that their digital CST platform (Ayla) is culturally and clinically adapted to the Australian market. • Partnerships: The focus is on building relationships with Australian healthcare organizations that are seeking digital tools to manage the increasing dementia burden. • Scalability: Australia is seen as a test market for how the product can be rolled out in English-speaking regions outside Europe, which increases the company's value in connection with a potential sale or partnership. 🛠️ Status of the Restructuring (February 2026) This is where Devika is currently spending most of her time to ensure the company's survival: • Creditor Negotiations: The company is in close dialogue with the trustee (Søren Volder). The goal is to clear up the debt so that Brain+ becomes an attractive investment again or can be sold. • Postponement of plan: The meeting regarding the final restructuring plan has just been proposed to be postponed to March 13, 2026. This is often interpreted as a positive sign that a real solution is being worked on rather than just a liquidation. • Focus on the core: Everything unnecessary has been cut. Devika is 100% focused on proving the value of the CST platform in the UK and Denmark to show the trustee that there is a sound business beneath the surface. 🚀 Commercial focus: UK and Denmark Even though there is noise around the economy, daily operations continue: • United Kingdom: Work with large nursing homes (like Agincare) continues. This is where the large volume contracts are to be secured. • Denmark: Brain+ maintains its position as a pioneer in the home market, which serves as a "proof-of-concept" for international markets·3 t sittenLittle andersbjørn and bøhman. This is a debate, and by definition, in a debate there must be room for both for and against. I know very well that you and the rest of the cheering squad don't understand a thing about it. You don't want debate, you cannot tolerate counter-arguments. You are only interested in hearing what you want to hear. I remind you, you have the option to mute me, please use it. Or use the advice I have given previously, that you create a Facebook group. Then you can sit and enjoy yourselves in it, well-protected, undisturbed and completely unopposed, and where you self-satisfied can enjoy your very own pseudo back-patting debate, where you are all oh so in agreement that you alone know, that you alone have insight, that you will get stinking rich on Brain and that Devika is God…all while you lose more and more money, but that doesn't matter, because you are right regardless - even when the money is 100% gone….hehehe·2 t sittenOverleif, maybe you could help us who are trying in the background to help Brain+ and save our assets, and possibly ask your niece, who, in relation to dementia coordinators, has decision-making power regarding the purchase of Ayla? That could help us who are actually trying to save Brain+, by contacting the right place. Ultimately, it might also give you some positive reception and take some of the pressure off. So, do you want or have the opportunity to ask your niece about the above and possibly whether it is dementia coordinators in general who cannot make the decision about buying Ayla or if some can? I am sure that you can actually become a resource, but we just need to find a way to bring that out. Do you perhaps have any suggestions on how we can help Brain+, possibly oonåelig funding to get past reconstruction and back to daily operations? I am not cutting you down, but here is an opening to help us who are trying to help Brain+ and I hope that you will accept the extended hand. Hope to hear your thoughts. Good day.
- ·8 t sitten( Skeptical ) "I can certainly understand the skepticism about the historical downgrades – the numbers haven't kept up with the rhetoric until now, we agree on that. But there are a few nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) rest on external research and evidence that is internationally recognized. It's not something Devika has sat and made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream-rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum-talk', but about the administrator's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product, is a more difficult discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I don't invest in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more."·5 t sittenSo there can be a reconstruction where current shareholders retain their shares?
- ·9 t sitten(Also writing the answer here with Devika ) "I do not agree that Devika is untrustworthy, but one must distinguish between a difficult market situation and personal credibility. Here are a few reasons why I still have faith in her work: 1. Product focus and execution: Under her leadership, Brain+ has actually delivered on the technical and clinical milestones. They have launched the CST products (Cognitive Stimulation Therapy) and created partnerships both in Denmark and internationally (e.g., in the UK). These are difficult results to achieve in the medtech industry. 2. Transparency during restructuring: It was the management itself that chose to enter restructuring to protect the company when long-term financing failed. This is a responsible action towards creditors and the company's future, rather than just letting it go bankrupt without a fight. 3. Tough market for Small Cap: The entire sector for small growth companies has been hit by an extreme drought in capital injection over the last few years. That the share price falls in such a market is rarely solely the CEO's fault, but rather an expression of a lack of market liquidity. 4. Her insight: She comes with deep experience from the industry, and it is she who has the network to secure the deals that will save the company now. Changing captain in the middle of a storm (restructuring) would be far more risky. Let's see what the plan from the administrator and management brings before we judge her. The most important thing right now is to save the assets for all involved
- ·10 t sitten · MuokattuI understand the situation for Brain+ is critical and I also have money at stake, although it sounds like it's not as much as others here. I am absolutely thrilled with the support that many are giving here and the work being put into helping Brain+ as much as possible... my BUT is that this work and this media attention that suddenly arises from this community, shouldn't it have been done by the company and perhaps already 2 years ago and continuously? I have all respect for the time you put into, of course, saving your own money, but there should have been a company that had already thought about and acted on all these initiatives that are now being put into play? There are many ways to run a company, I won't pretend to be an expert on that, but all in all, I miss some information and more announcements. It could also easily be that I don't fully understand all of this and expect them to react like multi-billion dollar companies..·8 t sittenI can certainly understand your skepticism about the historical downgrades – the numbers haven't matched the rhetoric until now, we agree on that. But there are a couple of nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) are based on external research and evidence that is internationally recognized. It's not something Devika just made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum talk', but about the trustee's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product is a harder discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I'm not investing in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more. Thanks for the good luck wish – in this end of the market, you always need a bit of luck, but I base my plan on the substance that, after all, lies in the product once the dust from the reconstruction has settled.·8 t sittenAnd adds that the price seeming low is in no way an indication that the stock is cheap. In fact, quite the opposite. It is a fact that stocks priced at such a level actually and very concretely belong among the supremely most expensive on the stock exchange, when assessed based on key figures and especially risks.
- ·1 päivä sittenNice with feedback
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
3 910 551
Myynti
Määrä
6 211 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 115 | - | - | ||
| 450 000 | - | - | ||
| 2 500 | - | - | ||
| 70 000 | - | - | ||
| 227 272 | - | - |
Ylin
0,002VWAP
Alin
0,002VaihtoMäärä
0 3 370 143
VWAP
Ylin
0,002Alin
0,002VaihtoMäärä
0 3 370 143
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9.2025 | |
| 2024 H2 -tulosraportti | 29.4.2025 | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
2025 H1 -tulosraportti
155 päivää sitten48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
| 2025 H2 -tulosraportti | 29.4. |
| Menneet tapahtumat | ||
|---|---|---|
| 2025 H1 -tulosraportti | 4.9.2025 | |
| 2024 H2 -tulosraportti | 29.4.2025 | |
| 2024 H1 -tulosraportti | 3.9.2024 | |
| 2023 H2 -tulosraportti | 7.5.2024 | |
| 2023 H1 -tulosraportti | 1.9.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·7 t sittenOverview ….. 🇦🇺 Australia: The Bridgehead to Asia-Pacific Australia is a central part of the company's global scaling strategy. Here are the specific points: • Validation of Ayla: Brain+ is working with leading Australian experts to ensure that their digital CST platform (Ayla) is culturally and clinically adapted to the Australian market. • Partnerships: The focus is on building relationships with Australian healthcare organizations that are seeking digital tools to manage the increasing dementia burden. • Scalability: Australia is seen as a test market for how the product can be rolled out in English-speaking regions outside Europe, which increases the company's value in connection with a potential sale or partnership. 🛠️ Status of the Restructuring (February 2026) This is where Devika is currently spending most of her time to ensure the company's survival: • Creditor Negotiations: The company is in close dialogue with the trustee (Søren Volder). The goal is to clear up the debt so that Brain+ becomes an attractive investment again or can be sold. • Postponement of plan: The meeting regarding the final restructuring plan has just been proposed to be postponed to March 13, 2026. This is often interpreted as a positive sign that a real solution is being worked on rather than just a liquidation. • Focus on the core: Everything unnecessary has been cut. Devika is 100% focused on proving the value of the CST platform in the UK and Denmark to show the trustee that there is a sound business beneath the surface. 🚀 Commercial focus: UK and Denmark Even though there is noise around the economy, daily operations continue: • United Kingdom: Work with large nursing homes (like Agincare) continues. This is where the large volume contracts are to be secured. • Denmark: Brain+ maintains its position as a pioneer in the home market, which serves as a "proof-of-concept" for international markets·3 t sittenLittle andersbjørn and bøhman. This is a debate, and by definition, in a debate there must be room for both for and against. I know very well that you and the rest of the cheering squad don't understand a thing about it. You don't want debate, you cannot tolerate counter-arguments. You are only interested in hearing what you want to hear. I remind you, you have the option to mute me, please use it. Or use the advice I have given previously, that you create a Facebook group. Then you can sit and enjoy yourselves in it, well-protected, undisturbed and completely unopposed, and where you self-satisfied can enjoy your very own pseudo back-patting debate, where you are all oh so in agreement that you alone know, that you alone have insight, that you will get stinking rich on Brain and that Devika is God…all while you lose more and more money, but that doesn't matter, because you are right regardless - even when the money is 100% gone….hehehe·2 t sittenOverleif, maybe you could help us who are trying in the background to help Brain+ and save our assets, and possibly ask your niece, who, in relation to dementia coordinators, has decision-making power regarding the purchase of Ayla? That could help us who are actually trying to save Brain+, by contacting the right place. Ultimately, it might also give you some positive reception and take some of the pressure off. So, do you want or have the opportunity to ask your niece about the above and possibly whether it is dementia coordinators in general who cannot make the decision about buying Ayla or if some can? I am sure that you can actually become a resource, but we just need to find a way to bring that out. Do you perhaps have any suggestions on how we can help Brain+, possibly oonåelig funding to get past reconstruction and back to daily operations? I am not cutting you down, but here is an opening to help us who are trying to help Brain+ and I hope that you will accept the extended hand. Hope to hear your thoughts. Good day.
- ·8 t sitten( Skeptical ) "I can certainly understand the skepticism about the historical downgrades – the numbers haven't kept up with the rhetoric until now, we agree on that. But there are a few nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) rest on external research and evidence that is internationally recognized. It's not something Devika has sat and made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream-rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum-talk', but about the administrator's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product, is a more difficult discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I don't invest in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more."·5 t sittenSo there can be a reconstruction where current shareholders retain their shares?
- ·9 t sitten(Also writing the answer here with Devika ) "I do not agree that Devika is untrustworthy, but one must distinguish between a difficult market situation and personal credibility. Here are a few reasons why I still have faith in her work: 1. Product focus and execution: Under her leadership, Brain+ has actually delivered on the technical and clinical milestones. They have launched the CST products (Cognitive Stimulation Therapy) and created partnerships both in Denmark and internationally (e.g., in the UK). These are difficult results to achieve in the medtech industry. 2. Transparency during restructuring: It was the management itself that chose to enter restructuring to protect the company when long-term financing failed. This is a responsible action towards creditors and the company's future, rather than just letting it go bankrupt without a fight. 3. Tough market for Small Cap: The entire sector for small growth companies has been hit by an extreme drought in capital injection over the last few years. That the share price falls in such a market is rarely solely the CEO's fault, but rather an expression of a lack of market liquidity. 4. Her insight: She comes with deep experience from the industry, and it is she who has the network to secure the deals that will save the company now. Changing captain in the middle of a storm (restructuring) would be far more risky. Let's see what the plan from the administrator and management brings before we judge her. The most important thing right now is to save the assets for all involved
- ·10 t sitten · MuokattuI understand the situation for Brain+ is critical and I also have money at stake, although it sounds like it's not as much as others here. I am absolutely thrilled with the support that many are giving here and the work being put into helping Brain+ as much as possible... my BUT is that this work and this media attention that suddenly arises from this community, shouldn't it have been done by the company and perhaps already 2 years ago and continuously? I have all respect for the time you put into, of course, saving your own money, but there should have been a company that had already thought about and acted on all these initiatives that are now being put into play? There are many ways to run a company, I won't pretend to be an expert on that, but all in all, I miss some information and more announcements. It could also easily be that I don't fully understand all of this and expect them to react like multi-billion dollar companies..·8 t sittenI can certainly understand your skepticism about the historical downgrades – the numbers haven't matched the rhetoric until now, we agree on that. But there are a couple of nuances that distinguish a 'school student's grade' from the reality Brain+ is in now: 1. Clinical validity is not self-invented: The comparison with the school student doesn't quite hold, as the clinical results and the CST method (Cognitive Stimulation Therapy) are based on external research and evidence that is internationally recognized. It's not something Devika just made up at her desk; it's the method behind the product that is valid. 2. From growth dream to tough reconstruction: There's a difference between 'Simon's dream rhetoric' and the situation the company is in now. A reconstruction is the ultimate acknowledgment that the previous strategy didn't hold water. Now it's not about 'momentum talk', but about the trustee's and creditors' assessment of whether there's a core business worth saving. 3. Execution under pressure: Yes, sales have been disappointing. But the fact that they have even gained a foothold in the UK and Denmark with a digital therapeutic product is a harder discipline than it seems. The HealthTech market is notorious for long sales cycles. 4. My risk/reward: I'm not investing in past mistakes, but in the possibility of a turnaround. At these price levels, all the negative things you mention are already priced in – and more. Thanks for the good luck wish – in this end of the market, you always need a bit of luck, but I base my plan on the substance that, after all, lies in the product once the dust from the reconstruction has settled.·8 t sittenAnd adds that the price seeming low is in no way an indication that the stock is cheap. In fact, quite the opposite. It is a fact that stocks priced at such a level actually and very concretely belong among the supremely most expensive on the stock exchange, when assessed based on key figures and especially risks.
- ·1 päivä sittenNice with feedback
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
First North Denmark
Määrä
Osto
3 910 551
Myynti
Määrä
6 211 000
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 3 115 | - | - | ||
| 450 000 | - | - | ||
| 2 500 | - | - | ||
| 70 000 | - | - | ||
| 227 272 | - | - |
Ylin
0,002VWAP
Alin
0,002VaihtoMäärä
0 3 370 143
VWAP
Ylin
0,002Alin
0,002VaihtoMäärä
0 3 370 143
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 370 143 | 3 370 143 | 0 | 0 |